Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCL (MCLelderly)

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2012 by European Mantle Cell Lymphoma Network
Sponsor:
Collaborators:
German Low Grade Lymphoma Study Group
Lymphoma Study Association
HOVON - Dutch Haemato-Oncology Association
Nordic Lymphoma Group
Information provided by (Responsible Party):
Dr. M. Dreyling (co-chairman), European Mantle Cell Lymphoma Network
ClinicalTrials.gov Identifier:
NCT00209209
First received: September 13, 2005
Last updated: September 6, 2012
Last verified: September 2012
  Purpose

The aim of this study is to answer the following independent questions in the treatment of mantle cell lymphomas:

  • Can rituximab-fludarabine, cyclophosphamide (R-FC) improve the reduction of lymphoma mass compared to rituximab-cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) and so become a new standard for initial cytoreductive therapy?
  • Can maintenance with rituximab substitute the interferon maintenance and even improve the progression free survival in patients after successful initial cytoreductive therapy?

Condition Intervention Phase
Lymphoma, Mantle-Cell
Drug: Rituximab
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone
Drug: Fludarabine
Drug: Interferon-alpha
Drug: pegylated formula Interferon-alpha 2b
Procedure: chemotherapy: R-CHOP
Procedure: chemotherapy: R-FC
Procedure: Interferon maintenance
Procedure: Rituximab maintenance
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Efficacy of Maintenance Therapy With Rituximab After Induction Chemotherapy (R-CHOP vs. R-FC) for Elderly Patients With Mantle Cell Lymphoma Not Suitable for Autologous Stem Cell Transplantation

Resource links provided by NLM:


Further study details as provided by European Mantle Cell Lymphoma Network:

Primary Outcome Measures:
  • First randomisation: Reduction of lymphoma mass measured by the complete remission (CR) rate
  • Second randomisation: progression-free survival after end of initial chemotherapy

Secondary Outcome Measures:
  • Survival after registration / first randomisation / second randomisation
  • Survival after start / end of initial therapy
  • Time to treatment failure after start of initial therapy
  • Progression free survival after registration / first randomisation / second randomisation
  • Side-effects of initial therapy
  • Side-effects of maintenance therapy

Estimated Enrollment: 570
Study Start Date: January 2004
Estimated Study Completion Date: December 2014
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
  1. randomisation: R-CHOP
  2. randomisation: IFN maintenance
Drug: Rituximab
antibody
Drug: Cyclophosphamide
chemotherapy
Drug: Doxorubicin
chemotherapy
Drug: Vincristine
chemotherapy
Drug: Prednisone
coricosteroide
Drug: Interferon-alpha
cytokine
Drug: pegylated formula Interferon-alpha 2b
cytokine
Procedure: chemotherapy: R-CHOP
immuno-chemotherapy
Procedure: Interferon maintenance
cytokine
Experimental: 2
  1. randomisation: R-FC
  2. randomisation: Rituximab maintnenance
Drug: Rituximab
antibody
Drug: Cyclophosphamide
chemotherapy
Drug: Fludarabine
chemotherapy
Procedure: chemotherapy: R-FC
immuno-chemotherapy
Procedure: Rituximab maintenance
antibody

Detailed Description:

This study investigates two independent questions in the treatment of elderly patients with mantle cell lymphomas:

  1. To test in elderly patients with advanced mantle cell lymphoma, whether rituximab plus a combination of fludarabine with cyclophosphamide (6 FC cycles) results in a higher reduction of lymphoma mass measured by the percentage of CR than rituximab combined with the standard chemotherapy scheme (8 CHOP cycles).
  2. To compare maintenance therapy with rituximab with maintenance with interferon-alpha or pegylated interferon for progression free survival, after 2 different regimens of induction chemo-immunotherapy in elderly patients with mantle cell lymphoma.

This study will be performed as a prospective, randomized, open-label multicenter phase III trial. All patients will be randomized for an initial cytoreductive therapy with R-FC or R-CHOP.

The parameter for the comparison of R-FC and R-CHOP will be the percentage of complete remissions after initial cytoreductive therapy. According to the known results of R-FC and R-CHOP in lymphoma therapy, a relevant difference between R-CHOP and R-FC in the overall response rates is not expected. For both therapies an overall response rate of about 90% is expected. Since it is well known that the prognosis of patients who do not reach at least a PR in the initial therapy is very poor, it will be also necessary to control this parameter during the study. If an unexpected relevant difference in the overall response rates is observed during the study, the initial randomisation should be stopped and all patients should be assigned to the superior therapy. In this case the CR rates will not be important for the choice of the initial therapy. If no relevant differences in the overall response rates are observed, a one sided Fisher test will be performed at the end of the recruitment to test whether the rate of CR's after R-FC is significantly improved compared to R-CHOP.

The statistical parameters for controlling the overall response rates and for testing the CR rates are chosen in the following way: The working significance level for all statistical evaluations in this part of the study will be set to alpha=0.05. The expected CR rate after R-CHOP is according to the observations about 50%; a clinical relevant improvement by R-FC would be a CR rate of 65%. Such an improvement should be detected by the one sided Fisher test with a power of about 95%. According to these parameters about 246 observations for each treatment would be necessary. To control the overall response rates, a difference of 85% to 95% will be clinically so relevant that initial randomisation should be terminated with a probability of about 95%. Overall response rates will be controlled by a restricted sequential procedure.

Patients achieving at least a partial remission after R-FC or R-CHOP will be randomised for interferon maintenance versus rituximab maintenance in order to evaluate the impact of maintenance therapy in progression free survival.

The improvement expected by the new maintenance with rituximab for progression free survival can be expressed by reduction of relative risk (rr). Since a risk reduction to 60% was observed for indolent lymphomas by interferon maintenance, this seems to be a clinical relevant improvement for the new maintenance therapy. For a working significance level alpha=0.05 and a power of 95% the number of events (relapse or death) necessary for a two sided fixed sample trial is about 200. During this study the progression free survival in patients after successful initial therapy will be monitored by an equivalent restricted sequential procedure with a maximum number of 240 observation.

In order to evaluate the impact of initial therapy and maintenance therapy on overall survival in this patients, a total follow up of about 15 years for this study is expected.

  Eligibility

Ages Eligible for Study:   60 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically proven mantle cell lymphoma according to the World Health Organization (WHO) classification, preferably confirmed by central pathology review before entering the study
  • Clinical stage II, III or IV
  • Previously untreated patients
  • Above the age of 65 years and older or patients at the age between 60 and 65, if not eligible for high dose chemotherapy
  • WHO performance grade 0, 1 or 2
  • Informed consent according to International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use/European Union Good Clinical Practice (ICH/EU GCP) and national/local regulations
  • Measurable disease. If, for example only bone marrow (BM) infiltration, patients can only undergo a second randomization if a CR is obtained.

Exclusion Criteria:

  • WHO performance of 3 or more
  • Known anti-murine antibody (HAMA) reactivity or known hypersensitivity to murine antibodies
  • Leukocytes <2.0x 10^9/l or thrombocytes <100x 10^9/l, unless clearly related to mantle cell lymphoma (MCL) bone marrow infiltration
  • Patients previously treated for lymphoma
  • Patients without measurable lesions; if, for example only bone marrow infiltration, patients may be included, but can only undergo a second randomization in case of a CR
  • Patients with stage I disease
  • Patients with central nervous system involvement
  • Patients with a history of autoimmune hemolytic anaemia or autoimmune thrombocytopenia
  • Patients with serious cardiac disease (uncontrolled arrhythmias, unstable angina, severe congestive heart failure)
  • Patients with serious pulmonary, neurological, endocrinological or other disorder interfering with full dosing of CHOP or FC chemotherapy
  • Liver enzymes >3x normal or bilirubin >2.5x normal (not due to lymphoma)
  • Creatinine >2x normal value, corrected for age and weight (not due to lymphoma)
  • Patients with unresolved hepatitis B or C infection or known HIV positive infection
  • Uncontrolled infection
  • Patients with a serious depression that needed therapy within the last 5 years
  • Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
  • Concomitant or previous malignancies other than basal cell or squamous cell skin cancer, in situ cervical cancer and other cancer for which the patient has been disease-free for at least 5 years
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00209209

Contacts
Contact: Michael Unterhalt, Dr. +49-89-7095 ext 4915 Michael.Unterhalt@med.uni-muenchen.de
Contact: Martin Dreyling, PhD +49-89-7095 ext 2202 Martin.Dreyling@med.uni-muenchen.de

Locations
Czech Republic
General University Hospital, 1St Department of Medicine Recruiting
Praha, Czech Republic, CZ-12808
Contact: Marek Trnény, MD    0042-2-2496-2061    trneny@cesnet.cz   
Principal Investigator: Marek Trnény, MD         
Denmark
Nordic Lymphoma Group Recruiting
Copenhagen, Denmark, DK-2100
Contact: Christian Geisler, MD    +45-3545-1146    geisler@rh.dk   
Principal Investigator: Christian Geisler, MD         
France
Groupe D´Etudes des Lymphomes De l´Adulte (GELA) Recruiting
Paris, France, F-75743
Contact: Guylène Chartier    +33-1-42499811    Guylene.chartier@chu-stlouis.fr   
Contact: Olivier Hermine, PhD    +33-1-44 49 52 83    hermine@necker.fr   
Principal Investigator: Olivier Hermine, PhD         
Germany
German Low Grade Study Group (Glsg) Recruiting
Munich, Germany, D-81377
Contact: Michael Unterhalt, Dr.    +49-89-7095 ext 4915    Michael.Unterhalt@med.uni-muenchen.de   
Contact: Martin Dreyling, PhD    +49-89-7095 ext 2202    Martin.Dreyling@med.uni-muenchen.de   
Principal Investigator: Martin Dreyling, PhD         
Italy
Ospedale Ferratotto, Divisione Di Ematologia Recruiting
Catania, Italy, I-95124
Contact: Francesco Di Raimondo, PhD    +39-095-7435911      
Principal Investigator: Francesco Di Raimondo, PhD         
Netherlands
HOVON - Dutch Haemato-Oncology Association (HOVON-Datacenter) Recruiting
Rotterdam, Netherlands, NL-3008 AE
Contact: Christel van Hooije    +31-10-4391568      
Contact: Hanneke C. Kluin-Nelemans, PhD    +31-50-3612354    j.c.kluin.nelemans@int.azg.nl   
Principal Investigator: Hanneke C. Kluin-Nelemans, PhD         
Poland
The Maria Sklodowska Memorial, Cancer Center - Inst. of Oncology Recruiting
Warszawa, Poland, PL-02-781
Contact: Jan Walewski, MD    +48-22-546-2223    walewski@coi.waw.pl   
Contact: Marek P Nowacki, MD    +48-22-546-2223      
Principal Investigator: Jan Walewski, MD         
Sponsors and Collaborators
European Mantle Cell Lymphoma Network
German Low Grade Lymphoma Study Group
Lymphoma Study Association
HOVON - Dutch Haemato-Oncology Association
Nordic Lymphoma Group
Investigators
Principal Investigator: Hanneke C. Kluin-Nelemans, PhD University Hospital Groningen, Dept. of Hematology
Study Chair: Martin Dreyling, PhD University Hospital Grosshadern/LMU, Dept. of Medicine III
  More Information

Additional Information:
Publications:

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Dr. M. Dreyling (co-chairman), Professor of Medicine, European Mantle Cell Lymphoma Network
ClinicalTrials.gov Identifier: NCT00209209     History of Changes
Other Study ID Numbers: MCL2004-1
Study First Received: September 13, 2005
Last Updated: September 6, 2012
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by European Mantle Cell Lymphoma Network:
Lymphoma, Mantle-Cell
Elderly patients
Chemotherapy
Maintenance therapy
C04.557.386.480.300.725.500
C15.604.515.569.480.300.725.500
C20.683.515.761.480.300.725.500

Additional relevant MeSH terms:
Lymphoma
Lymphoma, Mantle-Cell
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin
Cyclophosphamide
Rituximab
Interferons
Interferon-alpha
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions
Antirheumatic Agents
Therapeutic Uses
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Antiviral Agents
Anti-Infective Agents

ClinicalTrials.gov processed this record on September 22, 2014